Stability and inactivation of SARS coronavirus.
Identifieur interne : 002E26 ( PubMed/Corpus ); précédent : 002E25; suivant : 002E27Stability and inactivation of SARS coronavirus.
Auteurs : H F Rabenau ; J. Cinatl ; B. Morgenstern ; G. Bauer ; W. Preiser ; H W DoerrSource :
- Medical microbiology and immunology [ 0300-8584 ] ; 2005.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Coronavirus 229E, Human (drug effects), Coronavirus 229E, Human (growth & development), Coronavirus 229E, Human (pathogenicity), Disinfectants (chemistry), Disinfectants (pharmacology), Disinfection (methods), Hot Temperature, Humans, SARS Virus (drug effects), SARS Virus (growth & development), SARS Virus (pathogenicity), Vero Cells (virology).
- MESH :
- chemical , chemistry : Disinfectants.
- drug effects : Coronavirus 229E, Human, SARS Virus.
- growth & development : Coronavirus 229E, Human, SARS Virus.
- methods : Disinfection.
- pathogenicity : Coronavirus 229E, Human, SARS Virus.
- chemical , pharmacology : Disinfectants.
- virology : Vero Cells.
- Animals, Chlorocebus aethiops, Hot Temperature, Humans.
Abstract
The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56 degrees C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60 degrees C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agents tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.
DOI: 10.1007/s00430-004-0219-0
PubMed: 15118911
Links to Exploration step
pubmed:15118911Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stability and inactivation of SARS coronavirus.</title><author><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H F" last="Rabenau">H F Rabenau</name><affiliation><nlm:affiliation>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Germany. Rabenau@em.uni-frankfurt.de</nlm:affiliation></affiliation></author><author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name></author><author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name></author><author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name></author><author><name sortKey="Preiser, W" sort="Preiser, W" uniqKey="Preiser W" first="W" last="Preiser">W. Preiser</name></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15118911</idno><idno type="pmid">15118911</idno><idno type="doi">10.1007/s00430-004-0219-0</idno><idno type="wicri:Area/PubMed/Corpus">002E26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E26</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Stability and inactivation of SARS coronavirus.</title><author><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H F" last="Rabenau">H F Rabenau</name><affiliation><nlm:affiliation>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Germany. Rabenau@em.uni-frankfurt.de</nlm:affiliation></affiliation></author><author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name></author><author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name></author><author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name></author><author><name sortKey="Preiser, W" sort="Preiser, W" uniqKey="Preiser W" first="W" last="Preiser">W. Preiser</name></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name></author></analytic><series><title level="j">Medical microbiology and immunology</title><idno type="ISSN">0300-8584</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Coronavirus 229E, Human (drug effects)</term><term>Coronavirus 229E, Human (growth & development)</term><term>Coronavirus 229E, Human (pathogenicity)</term><term>Disinfectants (chemistry)</term><term>Disinfectants (pharmacology)</term><term>Disinfection (methods)</term><term>Hot Temperature</term><term>Humans</term><term>SARS Virus (drug effects)</term><term>SARS Virus (growth & development)</term><term>SARS Virus (pathogenicity)</term><term>Vero Cells (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Disinfectants</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus 229E, Human</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Coronavirus 229E, Human</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Disinfection</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Coronavirus 229E, Human</term><term>SARS Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Disinfectants</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Hot Temperature</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56 degrees C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60 degrees C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agents tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15118911</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-8584</ISSN><JournalIssue CitedMedium="Print"><Volume>194</Volume><Issue>1-2</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Medical microbiology and immunology</Title><ISOAbbreviation>Med. Microbiol. Immunol.</ISOAbbreviation></Journal><ArticleTitle>Stability and inactivation of SARS coronavirus.</ArticleTitle><Pagination><MedlinePgn>1-6</MedlinePgn></Pagination><Abstract><AbstractText>The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56 degrees C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60 degrees C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agents tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabenau</LastName><ForeName>H F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Germany. Rabenau@em.uni-frankfurt.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cinatl</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morgenstern</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Preiser</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Doerr</LastName><ForeName>H W</ForeName><Initials>HW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Med Microbiol Immunol</MedlineTA><NlmUniqueID>0314524</NlmUniqueID><ISSNLinking>0300-8584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004202">Disinfectants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028941" MajorTopicYN="N">Coronavirus 229E, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004202" MajorTopicYN="N">Disinfectants</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004203" MajorTopicYN="N">Disinfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="Y">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15118911</ArticleId><ArticleId IdType="doi">10.1007/s00430-004-0219-0</ArticleId><ArticleId IdType="pmc">PMC7086689</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):293-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12892961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Hosp Infect. 2000 Sep;46(1):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">11023724</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 3;361(9368):1519-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12737864</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trends Mol Med. 2003 Aug;9(8):325-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12928032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002E26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15118911
|texte= Stability and inactivation of SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15118911" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |